Clinical trials: Castration Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Abemaciclib With or Without Atezolizumab for mCRPC
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic…
- Trial name
- NCT04751929
- Testing
- Abemaciclib, Atezolizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Prostate Cancer
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Trial name
- NCT04631744
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Castration-Resistant Prostate Cancer
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.
- Trial name
- PREDICT (NCT01981109)
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Dendreon
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
This was a multiple-center, open-label, randomized, daily dose, two-sequence, expanded/phase II study in subjects with mHSPC or mCRPC who progressed after either abiraterone or enzalutamide treatment.
- Trial name
- NCT03899467
- Testing
- GT0918
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Prostate Cancer, Castration-resistant Prostate Cancer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05081193
- Testing
- Testosterone Undecanoate, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
- Conditions
- Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- PROSPER (NCT02003924)
- Testing
- Enzalutamide
- Where
- 397 sites in United States, Argentina and 30 more
- Volunteers
- 1,401 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
- Trial name
- CYCLONE 1 (NCT04408924)
- Testing
- Abemaciclib
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
This phase Ib/II trial studies the safety, side effects, best dose, and effectiveness of ribociclib when given with enzalutamide in treating patients with castrate-resistant prostate cancer that has spread from the primary site…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02555189
- Testing
- Enzalutamide, Ribociclib, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
A Study of Pertuzumab in Participants With Prostate Cancer
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
- Trial name
- NCT02480010
- Testing
- Pertuzumab
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
- Trial name
- READY (NCT00744497)
- Testing
- Dasatinib, Docetaxel, Prednisone
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 1,930 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
This phase II trial evaluated the impact of giving docetaxel together with lycopene supplements in treating patients with hormone-resistant prostate cancer not previously treated with chemotherapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01882985
- Testing
- Docetaxel, Lycopene
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Irvine
Prostatic Neoplasms
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment…
- Trial name
- SUN 1120 (NCT00676650)
- Testing
- Prednisone, sunitinib
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 873 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone…
- Trial name
- NCT03414034
- Testing
- Onvansertib, Abiraterone, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology